A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Triple Negative Breast Cancer|HER2-negative Breast Cancer|Non Small Cell Lung Cancer|Cervical Cancer|Castrate Resistant Prostate Cancer|Pancreatic Ductal Adenocarcinoma|Head-and-neck Squamous Cell Carcinoma|Endometrial Cancer|Ovarian Cancer|Gastric Cancer|Gastroesophageal-junction Cancer|Urothelial Carcinoma
DRUG: DR-0202
Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 during DR-0202 treatment through study completion (Safety and Tolerability), * Incidence, severity, and relationship of TEAEs (per CTCAE v5.0) through study completion (expected to be an average of 1 year) including but not limited to vital signs, clinical laboratory values (hematology, clinical chemistry, coagulation, urinalysis), 12-lead ECG
* Occurrence of DLTs during Cycle 1 (28 days), 28-day DLT Period and Treatment Duration / Study Completion
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas